ARTELO BIOSCIENCES INC (ARTL) Stock Price, Quote, News and Overview
NASDAQ:ARTL - Nasdaq - US04301G5080 - Common Stock - Currency: USD
ARTL Quote, Performance and Key Statistics
9.5
-3.77 (-28.41%)
The current stock price of ARTL is 9.5 USD. In the past month the price increased by 43.94%. In the past year, price increased by 18.6%.
ARTL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 56.39 | 735.35B | ||
| JNJ | JOHNSON & JOHNSON | 15.51 | 375.15B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.77 | 310.24B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.81 | 243.13B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.24 | 221.56B | ||
| MRK | MERCK & CO. INC. | 10.5 | 205.43B | ||
| PFE | PFIZER INC | 7.8 | 142.36B | ||
| SNY | SANOFI-ADR | 10.66 | 119.37B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.47 | 96.69B | ||
| GSK | GSK PLC-SPON ADR | 8.6 | 78.93B | ||
| ZTS | ZOETIS INC | 26.44 | 70.87B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 64.04 | 48.01B |
Related stock screener links
About ARTL
Company Profile
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. The company is headquartered in Solana Beach, California and currently employs 6 full-time employees. The company went IPO on 2015-10-13. The firm is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.
Company Info
ARTELO BIOSCIENCES INC
505 Lomas Santa Fe, Suite 160
Solana Beach CALIFORNIA 92037 US
CEO: Gregory D. Gorgas
Employees: 6
Phone: 18589257049
ARTELO BIOSCIENCES INC / ARTL FAQ
What is the stock price of ARTELO BIOSCIENCES INC today?
The current stock price of ARTL is 9.5 USD. The price decreased by -28.41% in the last trading session.
What is the ticker symbol for ARTELO BIOSCIENCES INC stock?
The exchange symbol of ARTELO BIOSCIENCES INC is ARTL and it is listed on the Nasdaq exchange.
On which exchange is ARTL stock listed?
ARTL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ARTELO BIOSCIENCES INC stock?
9 analysts have analysed ARTL and the average price target is 33.66 USD. This implies a price increase of 254.32% is expected in the next year compared to the current price of 9.5. Check the ARTELO BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ARTELO BIOSCIENCES INC worth?
ARTELO BIOSCIENCES INC (ARTL) has a market capitalization of 31.16M USD. This makes ARTL a Nano Cap stock.
How many employees does ARTELO BIOSCIENCES INC have?
ARTELO BIOSCIENCES INC (ARTL) currently has 6 employees.
What are the support and resistance levels for ARTELO BIOSCIENCES INC (ARTL) stock?
ARTELO BIOSCIENCES INC (ARTL) has a support level at 6.32 and a resistance level at 7.05. Check the full technical report for a detailed analysis of ARTL support and resistance levels.
Should I buy ARTELO BIOSCIENCES INC (ARTL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ARTL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ARTL, evaluating the profitability, health, valuation and growth aspects
- ARTELO BIOSCIENCES INC (ARTL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ARTELO BIOSCIENCES INC (ARTL) Sales and EPS estimates to see what analysts future expectations are.
- ARTELO BIOSCIENCES INC (ARTL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ARTELO BIOSCIENCES INC (ARTL) Insider and Institutional Ownership to learn about the owners and their transactions.
- ARTELO BIOSCIENCES INC (ARTL) Stock Chart to make your own analysis
- ARTELO BIOSCIENCES INC (ARTL) Latest news and press-releases to stay up to date.
Does ARTELO BIOSCIENCES INC (ARTL) stock pay dividends?
ARTL does not pay a dividend.
When does ARTELO BIOSCIENCES INC (ARTL) report earnings?
ARTELO BIOSCIENCES INC (ARTL) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of ARTELO BIOSCIENCES INC (ARTL)?
ARTELO BIOSCIENCES INC (ARTL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-17.94).
ARTL Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ARTL. When comparing the yearly performance of all stocks, ARTL is one of the better performing stocks in the market, outperforming 90.98% of all stocks.
ARTL Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ARTL. The financial health of ARTL is average, but there are quite some concerns on its profitability.
ARTL Financial Highlights
Over the last trailing twelve months ARTL reported a non-GAAP Earnings per Share(EPS) of -17.94. The EPS increased by 6.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -276.3% | ||
| ROE | -1489.57% | ||
| Debt/Equity | 0 |
ARTL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to ARTL. The Buy consensus is the average rating of analysts ratings from 9 analysts.